Acute Ischemic Stroke
TargED Biopharmaceuticals B.V. is involved in clinical research for acute ischemic stroke, with interest in treatment settings where rapid restoration of blood flow and neurological protection are central concerns.
- Neurovascular thrombosis
- Endovascular thrombectomy
- Acute stroke care
The sponsor’s work in this area reflects a focus on cerebrovascular disease and the management of time-sensitive ischemic injury.
Thrombotic Microangiopathies
The company also funds research in thrombotic microangiopathy, including conditions marked by small-vessel thrombosis, platelet consumption, and organ injury.
- Immune-mediated thrombotic thrombocytopenic purpura
- Microvascular thrombosis
- Platelet disorders
This therapeutic area highlights an interest in complex hematologic and vascular syndromes requiring targeted intervention.
Immune-Mediated Thrombotic Thrombocytopenic Purpura
Research activity includes immune-mediated thrombotic thrombocytopenic purpura, a severe thrombotic disorder associated with acute platelet depletion and systemic microvascular occlusion.
- Acute iTTP episodes
- Thrombocytopenia
- Thrombotic complications
These studies place emphasis on immune-driven coagulation abnormalities and their clinical consequences.
Healthy Volunteer Safety and Pharmacokinetics
The sponsor’s clinical portfolio also includes research in healthy volunteers, supporting early evaluation of safety, tolerability, and pharmacokinetics for investigational biopharmaceutical approaches.
- Safety assessment
- Tolerability
- Pharmacokinetic profiling
This area provides a foundation for development across thrombotic and vascular medicine programs.
